High prevalence of non-alcoholic fatty liver disease in patients with a first episode of acute ischemic stroke. Impact on disability and death

Introduction Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and it is associated with an increased risk of overall mortality being cardiovascular disease the most common cause of mortality. Strategies are needed to identify high risk groups for NAFLD to improve screening approaches. Moreover, there is a lack of information about the prevalence of NAFLD on patients with acute ischemic stroke (AIS) and the influence of NAFLD on the prognosis of the stroke. The aim of the study was to define the prevalence of NAFLD in patients with a first episode of AIS and the secondary aims were to evaluate the prevalence of NAFLD at different ages and its impact on the severity and prognosis of the AIS. Materials and methods Observational study including consecutive patients admitted for the first AIS from January 2005 to May 2018. Patients with harmful alcohol intake, other liver diseases and malignancies were excluded. Sociodemographic data, cardiovascular risk factors, comorbidities, and blood test at admission were reviewed. NAFLD and liver fibrosis were assessed with the serological scores Fatty Liver Index (FLI) and Fibrosis-4 respectively. NAFLD was defined by a FLI>60. Stroke severity and prognosis were evaluated with the National Institute of Health Stroke Scale and modified Rankin Scale respectively in patients aged from 40 to 79 years old. Results We included 1601 patients, 52.4% were female and median (IQR) age of 77 (66 – 83) years. The 41% of the total cohort had a FLI>60 with different prevalence according to age in decades: in 30-39 years: 35.7%; in 40-49: 47.5%; in 50-59: 51.1%, in 60-69: 56%, in 70-79: 41.4%; in 80-89: 34.9% (p<0.001). The presence of NAFLD did not impact on the severity or the prognosis of stroke. However, patients with NAFLD were younger than those without NAFLD (74 vs. 78; p<0.001). Conclusion Presence of NAFLD did not impact on disability and death after the stroke. However, patients with a first episode of stroke showed a high prevalence of NAFLD, especially at intermediate ages, and therefore, screening for NAFLD should be advisable.

[1]  M. Wang,et al.  Association Between Non-alcoholic Fatty Liver Disease and Risk of Stroke: A Systematic Review and Meta-Analysis , 2022, Frontiers in Cardiovascular Medicine.

[2]  A. Sanyal,et al.  Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals , 2022, Clinical and molecular hepatology.

[3]  M. Manns,et al.  The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality , 2021, The Lancet.

[4]  F. Lammert,et al.  Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  C. Byrne,et al.  Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. , 2021, The lancet. Gastroenterology & hepatology.

[6]  G. Marchesini,et al.  Non-alcoholic fatty liver disease: A patient guideline , 2021, JHEP reports : innovation in hepatology.

[7]  Takahisa Mori,et al.  Non-alcoholic fatty liver disease frequency and associated factors at admission of acute stroke , 2021, Hepatology International.

[8]  A. Mortara,et al.  Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population , 2021, Frontiers in Endocrinology.

[9]  Kyungdo Han,et al.  The Repeatedly Elevated Fatty Liver Index Is Associated With Increased Mortality: A Population-Based Cohort Study , 2021, Frontiers in Endocrinology.

[10]  Diji Kuriakose,et al.  Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives , 2020, International journal of molecular sciences.

[11]  C. Byrne,et al.  Complications, morbidity and mortality of nonalcoholic fatty liver disease. , 2020, Metabolism: clinical and experimental.

[12]  F. Violi,et al.  Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  F. Lammert,et al.  Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia. , 2019, Journal of hepatology.

[14]  N. Sattar,et al.  Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults , 2019, BMJ.

[15]  Z. Younossi,et al.  The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. , 2019, Journal of hepatology.

[16]  S. Fargion,et al.  Brain involvement in non-alcoholic fatty liver disease (NAFLD): A systematic review. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[17]  Fares Alahdab,et al.  Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2019, The Lancet Neurology.

[18]  Z. Younossi.  Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.

[19]  J. Fernández-Real,et al.  Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. , 2019, Medicina clinica.

[20]  C. Murray,et al.  On the road to universal health care in Indonesia, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet.

[21]  O. Ukkola,et al.  The association of non-alcoholic fatty liver disease and atrial fibrillation: a review , 2018, Annals of medicine.

[22]  Sven Van Poucke,et al.  Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis , 2018, European journal of gastroenterology & hepatology.

[23]  C. Iadecola,et al.  Ischemic stroke in cancer patients: A review of an underappreciated pathology , 2018, Annals of neurology.

[24]  H. Li,et al.  Non‐alcoholic fatty liver disease is associated with stroke severity and progression of brainstem infarctions , 2018, European journal of neurology.

[25]  M. Zheng,et al.  Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta‐analysis , 2018, Hepatology communications.

[26]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[27]  Yong Xu,et al.  Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis , 2017, Oncotarget.

[28]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[29]  S. Abd-Elsalam,et al.  Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. , 2017, Journal of clinical lipidology.

[30]  M. Allison,et al.  Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis , 2016, The American Journal of Gastroenterology.

[31]  Laurent Castera,et al.  Screening for liver fibrosis in the general population: a call for action. , 2016, The lancet. Gastroenterology & hepatology.

[32]  Corrado Barbui,et al.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. , 2016, Journal of hepatology.

[33]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[34]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[35]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[36]  Cheng-Li Lin,et al.  A population-based cohort study. , 2015 .

[37]  Yingyi Qin,et al.  Alcohol intake and risk of stroke: a dose-response meta-analysis of prospective studies. , 2014, International journal of cardiology.

[38]  M. Zoli,et al.  Changes of liver enzymes and bilirubin during ischemic stroke: mechanisms and possible significance , 2014, BMC Neurology.

[39]  Á. Brea,et al.  Epidemiología de la enfermedad vascular cerebral en España , 2013 .

[40]  Á. Brea,et al.  [Epidemiology of cerebrovascular disease in Spain]. , 2013, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

[41]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[42]  Paolo Crosignani,et al.  Fatty liver index and mortality: The cremona study in the 15th year of follow‐up , 2011, Hepatology.

[43]  G. Pera,et al.  Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain , 2010, European journal of gastroenterology & hepatology.

[44]  S. Phillips,et al.  Stroke Outcome in Those Over 80: A Multicenter Cohort Study Across Canada , 2008, Stroke.

[45]  F. Schmidt.  Meta-Analysis , 2008 .

[46]  Jamie L Banks,et al.  Outcomes Validity and Reliability of the Modified Rankin Scale: Implications for Stroke Clinical Trials: A Literature Review and Synthesis , 2007, Stroke.

[47]  Anna Castiglione,et al.  The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population , 2006, BMC gastroenterology.

[48]  Scott E Kasner,et al.  Clinical interpretation and use of stroke scales , 2006, The Lancet Neurology.

[49]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[50]  K. Furie,et al.  An evidence‐based causative classification system for acute ischemic stroke , 2005, Annals of neurology.

[51]  K. Pettigrew,et al.  Progression in acute stroke: value of the initial NIH stroke scale score on patient stratification in future trials. , 1999, Stroke.

[52]  H. Schouten,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.

[53]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[54]  S. Hatano,et al.  Experience from a multicentre stroke register: a preliminary report. , 1976, Bulletin of the World Health Organization.

[55]  D. Hay,et al.  Call for action. , 1971, Nursing mirror and midwives journal.

[56]  M. Sherman,et al.  A Preliminary Report , 1953 .